ANDA 90548, held by Apotex Inc. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 90548 (Atorvastatin Calcium), held by Apotex Inc, was first approved by FDA on May 29, 2012, with 11 approved supplements and 0 published complete response letters.
Atorvastatin Calcium Tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 2012 | Original application | Approved |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Dec 4, 2024 | Supplement 31Labeling · Standard review | Approved | None posted |
| Jul 25, 2023 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jul 25, 2023 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jul 25, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Nov 4, 2019 | Supplement 23Labeling · Standard review | Approved | None posted |
| Jan 17, 2019 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jun 7, 2018 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jun 7, 2018 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 6, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 6, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 29, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters